GWN Securities Inc. Sells 1,789 Shares of Amgen Inc. $AMGN

GWN Securities Inc. reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 41.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,542 shares of the medical research company’s stock after selling 1,789 shares during the period. GWN Securities Inc.’s holdings in Amgen were worth $716,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of AMGN. Brighton Jones LLC boosted its holdings in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the period. Oppenheimer Asset Management Inc. bought a new stake in shares of Amgen during the 1st quarter worth $276,000. Golden State Wealth Management LLC boosted its holdings in shares of Amgen by 5.5% during the 1st quarter. Golden State Wealth Management LLC now owns 1,933 shares of the medical research company’s stock worth $602,000 after buying an additional 101 shares during the period. Koshinski Asset Management Inc. boosted its holdings in shares of Amgen by 1.8% during the 1st quarter. Koshinski Asset Management Inc. now owns 11,302 shares of the medical research company’s stock worth $3,521,000 after buying an additional 202 shares during the period. Finally, Barnes Dennig Private Wealth Management LLC bought a new stake in shares of Amgen during the 1st quarter worth $4,304,000. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on AMGN. UBS Group decreased their price objective on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Citigroup increased their price target on shares of Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. Bank of America increased their price target on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a report on Friday, September 26th. Morgan Stanley increased their price target on shares of Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $300.94.

Amgen Trading Up 0.3%

Shares of AMGN stock opened at $292.09 on Wednesday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $335.88. The stock has a market cap of $157.25 billion, a price-to-earnings ratio of 23.88, a P/E/G ratio of 2.60 and a beta of 0.49. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a fifty day moving average of $287.82 and a 200-day moving average of $287.41.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.18 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the company posted $4.97 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were paid a $2.38 dividend. The ex-dividend date was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.3%. Amgen’s dividend payout ratio is currently 77.84%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.